---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-022572"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:15:03.219083+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review

## Summary
- Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.
- Organizational restructuring to reduce cost base ~60% (~$70M) and impact ~50% of workforce; R&D wound down, G&A cut ~50%.
- Board's Strategic Review Committee accelerating evaluation of alternatives including a sale of the company.
- Preliminary cash $326.5M at Q4 2025; expected ~$400M at Q1 2026 after $25M YUPELRI and $50M TRELEGY milestones received.
- YUPELRI FY2025 net sales $266.6M (+12% YoY); company expects ~$60-70M annualized cash flow from restructuring and YUPELRI.

## SEC filing metadata
- accession: 0001104659-26-022572
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/0001104659-26-022572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/tm267846d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-022572
- JSON: https://secwatch.observer/filing/0001104659-26-022572.json
- Plain text: https://secwatch.observer/filing/0001104659-26-022572.txt

## Source-grounded claims
- claim_id: d9246ac14ae0aaac8a8523e6076bc8c927fb1ee5
  claim: Theravance Biopharma, Inc. announced a restructuring with charges of approximately $5 million to $7 million affecting R&D and G&A functions (approximately 50% of the Company’s overall workforce).
  evidence_excerpt: On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is intended to reduce cost base by approximately 60% (or approximately $70 million) and expected to impact approximately 50% of the Company’s overall workforce. The Restructuring will be implemented over the next two quarters, with the Company expecting to incur approximately $5 million to $7 million in one-time cash severance costs related to the Restructuring.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/0001104659-26-022572-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.